ECSP088403A - Formulacion farmaceutica de absorción oral y su método de administracion - Google Patents
Formulacion farmaceutica de absorción oral y su método de administracionInfo
- Publication number
- ECSP088403A ECSP088403A EC2008008403A ECSP088403A ECSP088403A EC SP088403 A ECSP088403 A EC SP088403A EC 2008008403 A EC2008008403 A EC 2008008403A EC SP088403 A ECSP088403 A EC SP088403A EC SP088403 A ECSP088403 A EC SP088403A
- Authority
- EC
- Ecuador
- Prior art keywords
- micelle
- pharmaceutical formulation
- aerosol
- formulation
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Una formulación farmacéutica para absorber por la mucosa oral que incluye una cantidad efectiva de (a) un agente farmacéutico en forma de micela combinada, (b) al menos unCompuesto formador de micela seleccionado del grupo de sulfato alquilo de metal alcalino y monooleato de sorbitan polioxietileno, (c) un copolímero bloque de polioxietileno y polioxipropileno, (d) al menos un compuesto formador de micela adicional y (e) un disolvente adecuado. La invención proporciona además un dispensador de dosis graduado (aerosol y no aerosol) que contiene la presente formulación y un método de administración de insulina con un dispensador de dosis graduado que incluye administrar dosis múltiples de una formulación que contiene insulina antes y después de cada comida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2005/001816 WO2007062494A1 (en) | 2005-11-30 | 2005-11-30 | Orally absorbed pharmaceutical formulation and method of administration |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP088403A true ECSP088403A (es) | 2008-05-30 |
Family
ID=38091821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2008008403A ECSP088403A (es) | 2005-11-30 | 2008-04-25 | Formulacion farmaceutica de absorción oral y su método de administracion |
Country Status (15)
Country | Link |
---|---|
US (2) | US20090214657A1 (es) |
EP (1) | EP1954242A4 (es) |
JP (1) | JP2009517410A (es) |
CN (1) | CN101309668A (es) |
AP (1) | AP2008004447A0 (es) |
AR (1) | AR057180A1 (es) |
AU (1) | AU2005338631B2 (es) |
BR (1) | BRPI0520704A2 (es) |
CA (1) | CA2630578C (es) |
EA (1) | EA200800979A1 (es) |
EC (1) | ECSP088403A (es) |
IL (1) | IL191531A0 (es) |
NZ (1) | NZ567601A (es) |
UY (1) | UY29905A1 (es) |
WO (1) | WO2007062494A1 (es) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009015456A1 (en) * | 2007-07-30 | 2009-02-05 | Generex Pharmaceuticals Inc. | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray |
CN101422431B (zh) * | 2007-12-28 | 2011-03-23 | 上海医药工业研究院 | 胰岛素经鼻给药制剂 |
RS56632B1 (sr) | 2008-10-17 | 2018-03-30 | Sanofi Aventis Deutschland | Kombinacija insulina i glp-1-agonista |
CN100594929C (zh) * | 2009-06-24 | 2010-03-24 | 薛南荣 | 口服胰岛素药物及其制备方法 |
AU2010317995B2 (en) | 2009-11-13 | 2014-04-17 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine |
CN102711804B (zh) | 2009-11-13 | 2015-09-16 | 赛诺菲-安万特德国有限公司 | 包含glp-1激动剂和甲硫氨酸的药物组合物 |
RU2012133075A (ru) * | 2010-01-12 | 2014-02-20 | Ново Нордиск А/С | Фармацевтическая композиция для перорального введения инсулиновых пептидов |
AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
JP6199186B2 (ja) | 2010-08-30 | 2017-09-20 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病の治療用の医薬の製造のためのave0010の使用 |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
CN102228680B (zh) * | 2011-06-14 | 2013-02-27 | 中国人民解放军第三0二医院 | 胸腺肽的磷脂/胆盐复合胶束及其制备方法和制剂 |
JP2014518270A (ja) * | 2011-06-27 | 2014-07-28 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | トロイダル医薬製剤 |
JP6367115B2 (ja) | 2011-08-29 | 2018-08-01 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 2型糖尿病患者の血糖コントロールに使用する組合せ医薬 |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
JP6457484B2 (ja) | 2013-04-03 | 2019-01-23 | サノフイSanofi | インスリンの長時間作用型製剤による糖尿病の治療 |
US9687455B2 (en) | 2014-08-14 | 2017-06-27 | John Daniel Dobak | Sodium tetradecyl sulfate formulations for treatment of adipose tissue |
DK3006045T3 (en) | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
MX2017007699A (es) | 2014-12-12 | 2017-09-18 | Sanofi Aventis Deutschland | Formulacion de proporcion fija de insulina glargina/lixisenatida. |
US9351945B1 (en) | 2015-02-27 | 2016-05-31 | John Daniel Dobak, III | Reduction of adipose tissue |
TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患治療 |
TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第2型糖尿病病患之治療 |
WO2017060500A1 (en) | 2015-10-07 | 2017-04-13 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
US11166912B2 (en) | 2016-03-03 | 2021-11-09 | Ctt Pharma Inc. | Orally administrable composition |
US11298336B2 (en) | 2019-05-30 | 2022-04-12 | Soluble Technologies, Inc. | Water soluble formulation |
US11786475B2 (en) | 2020-07-22 | 2023-10-17 | Soluble Technologies Inc. | Film-based dosage form |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1319886C (en) * | 1987-02-03 | 1993-07-06 | Alberto Ferro | Mixed micelle solutions |
US5817321A (en) * | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
JPH08506319A (ja) * | 1992-10-08 | 1996-07-09 | ヴァレリ ユ. アラホフ | ミセル中に組み込まれた抗−新生物性組成物 |
TW402506B (en) * | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
DE19733651A1 (de) * | 1997-08-04 | 1999-02-18 | Boehringer Ingelheim Pharma | Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole |
IL122084A (en) * | 1997-10-31 | 1999-09-22 | Lurident Ltd | Formulation for personal care with mucoadhesive properties |
US6063762A (en) * | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
US6017545A (en) * | 1998-02-10 | 2000-01-25 | Modi; Pankaj | Mixed micellar delivery system and method of preparation |
US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
US6436367B1 (en) * | 1998-12-21 | 2002-08-20 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
US6375975B1 (en) * | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
US6312665B1 (en) * | 1998-12-21 | 2001-11-06 | Generex Pharmaceuticals Incorporated | Aerosol formulations for buccal and pulmonary application |
US6451286B1 (en) * | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
US6485706B1 (en) * | 1999-06-04 | 2002-11-26 | Delrx Pharmaceutical Corp. | Formulations comprising dehydrated particles of pharma-ceutical agents and process for preparing the same |
-
2005
- 2005-11-30 AU AU2005338631A patent/AU2005338631B2/en not_active Ceased
- 2005-11-30 CA CA2630578A patent/CA2630578C/en not_active Expired - Fee Related
- 2005-11-30 US US12/085,783 patent/US20090214657A1/en not_active Abandoned
- 2005-11-30 NZ NZ567601A patent/NZ567601A/en not_active IP Right Cessation
- 2005-11-30 JP JP2008542566A patent/JP2009517410A/ja active Pending
- 2005-11-30 EP EP05814246A patent/EP1954242A4/en not_active Withdrawn
- 2005-11-30 WO PCT/CA2005/001816 patent/WO2007062494A1/en active Application Filing
- 2005-11-30 EA EA200800979A patent/EA200800979A1/ru unknown
- 2005-11-30 AP AP2008004447A patent/AP2008004447A0/xx unknown
- 2005-11-30 CN CNA2005800520768A patent/CN101309668A/zh active Pending
- 2005-11-30 BR BRPI0520704-5A patent/BRPI0520704A2/pt not_active IP Right Cessation
-
2006
- 2006-11-08 UY UY29905A patent/UY29905A1/es not_active Application Discontinuation
- 2006-11-27 AR ARP060105216A patent/AR057180A1/es unknown
-
2008
- 2008-04-25 EC EC2008008403A patent/ECSP088403A/es unknown
- 2008-05-18 IL IL191531A patent/IL191531A0/en unknown
-
2012
- 2012-02-29 US US13/408,133 patent/US20120171259A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EA200800979A1 (ru) | 2008-10-30 |
NZ567601A (en) | 2010-12-24 |
UY29905A1 (es) | 2007-05-31 |
AR057180A1 (es) | 2007-11-21 |
AU2005338631A1 (en) | 2007-06-07 |
CA2630578C (en) | 2014-04-15 |
CA2630578A1 (en) | 2007-06-07 |
AU2005338631B2 (en) | 2011-12-01 |
BRPI0520704A2 (pt) | 2009-05-19 |
IL191531A0 (en) | 2008-12-29 |
JP2009517410A (ja) | 2009-04-30 |
CN101309668A (zh) | 2008-11-19 |
US20090214657A1 (en) | 2009-08-27 |
AP2008004447A0 (en) | 2008-04-30 |
US20120171259A1 (en) | 2012-07-05 |
WO2007062494A1 (en) | 2007-06-07 |
EP1954242A4 (en) | 2012-08-01 |
EP1954242A1 (en) | 2008-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP088403A (es) | Formulacion farmaceutica de absorción oral y su método de administracion | |
AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
DK1257254T3 (da) | Formuleringer indeholdende et anticholinergt lægemiddel til behandling af kronisk obstruktiv lungesygdom | |
AR101593A2 (es) | Formulación superfina de formoterol | |
HRP20060147B1 (hr) | Terapijski sustav s kontroliranim otpuštanjem za nazalnu primjenu | |
TN2009000504A1 (en) | Pharmaceutical formulation in mixed micellar form and dispenser for oral delivery of agents as a spray | |
WO2005041925A3 (en) | Compositions and dosage forms for enhanced absorption | |
SG157406A1 (en) | Oral medicament for the modified release of at least one active principle, in multi-microcapsule form | |
ECSP10010224A (es) | Formulaciones líquidas de hormona luteinizante (lh). | |
FR2878161B1 (fr) | Forme medicamenteuse orale, solide et concue pour eviter le mesusage | |
BR112014008602A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dosagem medida, métodos para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica | |
WO2007020204A3 (en) | Hfc solution formulations for inhalation containing salbutamol hydrochloride or salbutamol citrate | |
MX336225B (es) | Composiciones que comprenden sulfato de salbutamol. | |
SG149054A1 (en) | Multiparticulate formulations for oral delivery | |
AR034813A1 (es) | Composiciones farmaceuticas y uso de las mismas | |
WO2013104892A8 (en) | Application of high dose compounds via inhalation | |
WO2008106689A3 (en) | Breakthrough pain management | |
PE20011271A1 (es) | Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares | |
BRPI0607990A2 (pt) | formulação de um aerossol farmacêutico para inaladores dosimetrados pressurizados contendo um agente seqüestrante, uso do agente sequestrante, inalador de dosimetrado pressurizado e método de preenchimento do inalador de aerossol | |
DE60329968D1 (de) | Dosierungsformen enthaltend Thyroidhormone und deren Herstellungsverfahren | |
NO20083759L (no) | Doserings aerosoler for administrering av farmasoytiske preparater | |
WO2008079343A3 (en) | Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients | |
SE0401612L (sv) | Inhalator som använder balja | |
CO6270213A2 (es) | Composiciones farmaceuticas que comprenden acido montelukast y un unhibidor depde-4 o un corticoesteroide inhalado para administracion por inhalacion | |
JO3024B1 (ar) | صيغ أيروسول صيدلانية من الفرموتيرول وبكلوميتازون داي بروبيونات |